Jennifer Kiser
Concepts (358)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antiviral Agents | 32 | 2025 | 704 | 6.360 |
Why?
| Anti-HIV Agents | 35 | 2025 | 747 | 4.630 |
Why?
| HIV Infections | 56 | 2025 | 2703 | 4.440 |
Why?
| Hepatitis C | 13 | 2023 | 233 | 4.330 |
Why?
| Adenine | 29 | 2025 | 255 | 4.260 |
Why?
| Hepatitis C, Chronic | 14 | 2025 | 153 | 4.050 |
Why?
| Ribavirin | 15 | 2020 | 92 | 3.840 |
Why?
| Sofosbuvir | 13 | 2025 | 58 | 3.780 |
Why?
| Drug Interactions | 21 | 2019 | 360 | 3.370 |
Why?
| Tenofovir | 30 | 2025 | 231 | 3.320 |
Why?
| Tandem Mass Spectrometry | 17 | 2025 | 450 | 2.450 |
Why?
| Hepacivirus | 11 | 2025 | 234 | 2.010 |
Why?
| Dried Blood Spot Testing | 13 | 2024 | 91 | 1.950 |
Why?
| Proline | 5 | 2019 | 78 | 1.890 |
Why?
| Organophosphates | 15 | 2025 | 120 | 1.820 |
Why?
| Oligopeptides | 8 | 2015 | 257 | 1.810 |
Why?
| Emtricitabine | 19 | 2025 | 168 | 1.780 |
Why?
| Organophosphonates | 12 | 2014 | 91 | 1.600 |
Why?
| Ritonavir | 8 | 2021 | 72 | 1.470 |
Why?
| Protease Inhibitors | 4 | 2020 | 103 | 1.420 |
Why?
| Chromatography, Liquid | 14 | 2025 | 374 | 1.350 |
Why?
| Coinfection | 5 | 2024 | 131 | 1.330 |
Why?
| Benzimidazoles | 6 | 2025 | 158 | 1.240 |
Why?
| Phosphorous Acids | 3 | 2019 | 13 | 1.220 |
Why?
| Fluorenes | 4 | 2020 | 40 | 1.120 |
Why?
| Pyrophosphatases | 3 | 2016 | 21 | 1.100 |
Why?
| Hepatitis B | 4 | 2024 | 61 | 1.080 |
Why?
| Nucleotides | 3 | 2016 | 117 | 1.080 |
Why?
| Medication Adherence | 16 | 2022 | 573 | 0.970 |
Why?
| Anti-Retroviral Agents | 5 | 2019 | 230 | 0.950 |
Why?
| Drug Therapy, Combination | 12 | 2018 | 1009 | 0.880 |
Why?
| Pyridines | 5 | 2015 | 469 | 0.860 |
Why?
| Humans | 101 | 2025 | 128524 | 0.790 |
Why?
| Polyphosphates | 7 | 2022 | 37 | 0.790 |
Why?
| Erythrocytes | 8 | 2016 | 670 | 0.790 |
Why?
| Cell Phone | 1 | 2022 | 70 | 0.770 |
Why?
| HIV Protease Inhibitors | 5 | 2011 | 61 | 0.760 |
Why?
| Reverse Transcriptase Inhibitors | 5 | 2014 | 81 | 0.760 |
Why?
| Viral Load | 11 | 2024 | 450 | 0.740 |
Why?
| Membrane Transport Proteins | 4 | 2016 | 148 | 0.730 |
Why?
| Simeprevir | 2 | 2018 | 8 | 0.730 |
Why?
| HIV-1 | 7 | 2021 | 840 | 0.710 |
Why?
| Sulfonamides | 5 | 2019 | 500 | 0.700 |
Why?
| Mobile Applications | 1 | 2022 | 158 | 0.680 |
Why?
| Therapies, Investigational | 1 | 2019 | 14 | 0.660 |
Why?
| Heterocyclic Compounds, 3-Ring | 2 | 2023 | 30 | 0.630 |
Why?
| Respiratory Syncytial Virus Infections | 1 | 2020 | 117 | 0.630 |
Why?
| Adult | 45 | 2025 | 35315 | 0.610 |
Why?
| Leukocytes, Mononuclear | 9 | 2025 | 538 | 0.610 |
Why?
| Male | 55 | 2025 | 62883 | 0.610 |
Why?
| Ethanol | 1 | 2023 | 585 | 0.600 |
Why?
| Middle Aged | 39 | 2025 | 30893 | 0.600 |
Why?
| Pyridazines | 2 | 2021 | 50 | 0.590 |
Why?
| Antiretroviral Therapy, Highly Active | 4 | 2015 | 266 | 0.580 |
Why?
| Lung Transplantation | 1 | 2020 | 275 | 0.580 |
Why?
| Solid Phase Extraction | 2 | 2014 | 20 | 0.570 |
Why?
| Pyrimidinones | 2 | 2008 | 102 | 0.550 |
Why?
| Liver | 2 | 2016 | 1827 | 0.540 |
Why?
| HIV Integrase Inhibitors | 1 | 2018 | 70 | 0.540 |
Why?
| Inosine | 1 | 2016 | 12 | 0.540 |
Why?
| Guanosine | 1 | 2016 | 40 | 0.530 |
Why?
| Pharmacogenomic Variants | 1 | 2016 | 35 | 0.520 |
Why?
| Female | 50 | 2025 | 68127 | 0.510 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2015 | 475 | 0.510 |
Why?
| Purines | 1 | 2016 | 169 | 0.500 |
Why?
| Drug Monitoring | 3 | 2022 | 184 | 0.490 |
Why?
| Carbamates | 2 | 2025 | 45 | 0.490 |
Why?
| Drug Discovery | 1 | 2016 | 130 | 0.490 |
Why?
| Isoniazid | 2 | 2012 | 60 | 0.480 |
Why?
| Serum | 1 | 2015 | 56 | 0.470 |
Why?
| Kidney | 4 | 2016 | 1305 | 0.470 |
Why?
| Adenosine | 1 | 2016 | 211 | 0.470 |
Why?
| Intracellular Space | 1 | 2014 | 71 | 0.460 |
Why?
| Pre-Exposure Prophylaxis | 5 | 2020 | 202 | 0.450 |
Why?
| Telemedicine | 1 | 2022 | 778 | 0.440 |
Why?
| HIV | 4 | 2019 | 226 | 0.440 |
Why?
| Priapism | 1 | 2013 | 9 | 0.440 |
Why?
| Receptors, Adrenergic, alpha | 1 | 2013 | 25 | 0.440 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2013 | 32 | 0.440 |
Why?
| Deoxycytidine | 6 | 2017 | 164 | 0.430 |
Why?
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 20 | 0.430 |
Why?
| Antitubercular Agents | 2 | 2012 | 197 | 0.430 |
Why?
| Hepatitis B, Chronic | 3 | 2022 | 18 | 0.400 |
Why?
| Hepatitis B virus | 4 | 2024 | 35 | 0.400 |
Why?
| Treatment Outcome | 13 | 2025 | 10163 | 0.400 |
Why?
| Gastric Bypass | 1 | 2014 | 107 | 0.400 |
Why?
| Alanine | 5 | 2025 | 141 | 0.370 |
Why?
| Prospective Studies | 17 | 2022 | 7043 | 0.370 |
Why?
| Phenotype | 2 | 2016 | 3050 | 0.360 |
Why?
| HIV Seronegativity | 1 | 2010 | 25 | 0.360 |
Why?
| Antacids | 1 | 2010 | 13 | 0.360 |
Why?
| Pyrrolidinones | 1 | 2010 | 29 | 0.350 |
Why?
| Genotype | 6 | 2023 | 1831 | 0.350 |
Why?
| Pyrimidines | 3 | 2021 | 444 | 0.350 |
Why?
| Patient Compliance | 3 | 2017 | 562 | 0.340 |
Why?
| Tuberculosis | 2 | 2012 | 275 | 0.330 |
Why?
| Pregnancy Complications, Infectious | 3 | 2025 | 335 | 0.330 |
Why?
| Pharmacy Service, Hospital | 1 | 2011 | 93 | 0.330 |
Why?
| Plasma | 4 | 2016 | 201 | 0.330 |
Why?
| Blood Chemical Analysis | 4 | 2019 | 96 | 0.330 |
Why?
| Reproducibility of Results | 8 | 2016 | 3023 | 0.320 |
Why?
| Area Under Curve | 4 | 2018 | 281 | 0.320 |
Why?
| Uridine Monophosphate | 2 | 2019 | 15 | 0.310 |
Why?
| Drug Prescriptions | 1 | 2011 | 250 | 0.310 |
Why?
| Young Adult | 17 | 2025 | 12320 | 0.300 |
Why?
| Fluorobenzenes | 1 | 2008 | 15 | 0.300 |
Why?
| Adolescent | 20 | 2020 | 20213 | 0.290 |
Why?
| Drug Stability | 5 | 2016 | 144 | 0.290 |
Why?
| Guidelines as Topic | 1 | 2009 | 260 | 0.280 |
Why?
| Atazanavir Sulfate | 5 | 2015 | 41 | 0.280 |
Why?
| Liver Transplantation | 1 | 2014 | 795 | 0.270 |
Why?
| Sensitivity and Specificity | 5 | 2014 | 1820 | 0.270 |
Why?
| Half-Life | 3 | 2015 | 144 | 0.270 |
Why?
| Esomeprazole | 1 | 2006 | 6 | 0.260 |
Why?
| Anti-Ulcer Agents | 1 | 2006 | 14 | 0.260 |
Why?
| Glycerophospholipids | 2 | 2023 | 32 | 0.260 |
Why?
| Pharmacology, Clinical | 1 | 2006 | 9 | 0.260 |
Why?
| Sustained Virologic Response | 3 | 2023 | 36 | 0.250 |
Why?
| Hepatocytes | 3 | 2016 | 213 | 0.250 |
Why?
| Education | 1 | 2006 | 99 | 0.250 |
Why?
| Heterocyclic Compounds, 4 or More Rings | 1 | 2025 | 19 | 0.240 |
Why?
| Proton Pump Inhibitors | 1 | 2006 | 98 | 0.240 |
Why?
| South Africa | 4 | 2015 | 192 | 0.240 |
Why?
| Phosphates | 3 | 2015 | 167 | 0.230 |
Why?
| Anemia | 2 | 2016 | 156 | 0.220 |
Why?
| Biomarkers | 5 | 2023 | 3881 | 0.220 |
Why?
| Health Personnel | 1 | 2009 | 646 | 0.210 |
Why?
| Variola virus | 1 | 2022 | 1 | 0.210 |
Why?
| Smallpox | 1 | 2022 | 8 | 0.210 |
Why?
| World Health Organization | 1 | 2022 | 109 | 0.200 |
Why?
| Delivery of Health Care | 1 | 2009 | 892 | 0.200 |
Why?
| Blood Platelets | 1 | 2025 | 369 | 0.190 |
Why?
| Linear Models | 2 | 2014 | 816 | 0.190 |
Why?
| Cross-Over Studies | 4 | 2020 | 513 | 0.190 |
Why?
| Cyclopropanes | 2 | 2019 | 88 | 0.190 |
Why?
| Lopinavir | 3 | 2020 | 30 | 0.190 |
Why?
| Point-of-Care Systems | 1 | 2023 | 150 | 0.180 |
Why?
| Dideoxynucleosides | 2 | 2023 | 20 | 0.180 |
Why?
| Phosphorylation | 2 | 2015 | 1681 | 0.180 |
Why?
| Interferons | 2 | 2019 | 192 | 0.170 |
Why?
| Aminoisobutyric Acids | 1 | 2019 | 7 | 0.170 |
Why?
| Drug Administration Schedule | 3 | 2019 | 757 | 0.170 |
Why?
| Neutrophils | 1 | 2025 | 1188 | 0.160 |
Why?
| Lactams, Macrocyclic | 1 | 2019 | 49 | 0.160 |
Why?
| Homosexuality, Male | 2 | 2017 | 176 | 0.160 |
Why?
| Pyrrolidines | 1 | 2019 | 64 | 0.160 |
Why?
| Quinoxalines | 1 | 2019 | 65 | 0.160 |
Why?
| Leucine | 1 | 2019 | 108 | 0.160 |
Why?
| Nucleic Acids | 1 | 2019 | 60 | 0.160 |
Why?
| Quality Control | 2 | 2015 | 156 | 0.150 |
Why?
| Organic Anion Transport Protein 1 | 2 | 2008 | 6 | 0.150 |
Why?
| Oxazines | 1 | 2018 | 26 | 0.150 |
Why?
| Multidrug Resistance-Associated Proteins | 2 | 2008 | 36 | 0.150 |
Why?
| Directly Observed Therapy | 1 | 2017 | 14 | 0.140 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 626 | 0.140 |
Why?
| Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2017 | 17 | 0.140 |
Why?
| Nitriles | 2 | 2021 | 160 | 0.140 |
Why?
| Liver Cirrhosis | 1 | 2019 | 273 | 0.140 |
Why?
| Pregnancy Outcome | 1 | 2020 | 383 | 0.140 |
Why?
| Pharmacogenetics | 2 | 2016 | 171 | 0.140 |
Why?
| Inosine Triphosphate | 1 | 2016 | 3 | 0.140 |
Why?
| Anemia, Hemolytic | 1 | 2016 | 17 | 0.140 |
Why?
| Darunavir | 2 | 2014 | 17 | 0.140 |
Why?
| Deoxyadenine Nucleotides | 1 | 2016 | 13 | 0.140 |
Why?
| Deoxycytosine Nucleotides | 1 | 2016 | 11 | 0.140 |
Why?
| Guanosine Triphosphate | 1 | 2016 | 92 | 0.130 |
Why?
| Glass | 1 | 2016 | 43 | 0.130 |
Why?
| Pharmacy | 1 | 2017 | 32 | 0.130 |
Why?
| Drug Combinations | 3 | 2025 | 323 | 0.130 |
Why?
| Molecular Targeted Therapy | 1 | 2019 | 387 | 0.130 |
Why?
| Zika Virus | 1 | 2017 | 77 | 0.130 |
Why?
| Genitalia | 1 | 2016 | 30 | 0.130 |
Why?
| Syringes | 1 | 2016 | 37 | 0.130 |
Why?
| Disease Transmission, Infectious | 1 | 2017 | 57 | 0.130 |
Why?
| Drug Packaging | 1 | 2016 | 41 | 0.130 |
Why?
| Drug and Narcotic Control | 1 | 2016 | 28 | 0.130 |
Why?
| Viremia | 3 | 2022 | 130 | 0.130 |
Why?
| Pyridones | 1 | 2018 | 159 | 0.130 |
Why?
| Fibroblast Growth Factors | 2 | 2014 | 171 | 0.130 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2011 | 411 | 0.120 |
Why?
| Polymers | 1 | 2019 | 471 | 0.120 |
Why?
| Analgesics | 1 | 2017 | 165 | 0.120 |
Why?
| Retrospective Studies | 4 | 2020 | 14460 | 0.120 |
Why?
| Practice Guidelines as Topic | 2 | 2016 | 1490 | 0.120 |
Why?
| Piperazines | 1 | 2018 | 334 | 0.120 |
Why?
| Biological Assay | 1 | 2016 | 118 | 0.120 |
Why?
| Cytosol | 1 | 2016 | 213 | 0.120 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2016 | 2065 | 0.120 |
Why?
| Rectum | 1 | 2016 | 169 | 0.120 |
Why?
| Creatinine | 2 | 2018 | 475 | 0.120 |
Why?
| Brain Diseases | 1 | 2016 | 134 | 0.120 |
Why?
| Population | 1 | 2015 | 33 | 0.120 |
Why?
| Nonlinear Dynamics | 1 | 2015 | 88 | 0.120 |
Why?
| Mental Health Services | 1 | 2019 | 399 | 0.120 |
Why?
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 134 | 0.120 |
Why?
| Virus Replication | 1 | 2017 | 444 | 0.120 |
Why?
| Liver Function Tests | 1 | 2015 | 109 | 0.120 |
Why?
| CD4 Lymphocyte Count | 2 | 2015 | 265 | 0.110 |
Why?
| Infectious Disease Transmission, Vertical | 3 | 2025 | 165 | 0.110 |
Why?
| Administration, Oral | 3 | 2019 | 757 | 0.110 |
Why?
| Pharmaceutical Preparations | 1 | 2016 | 170 | 0.110 |
Why?
| Adenosine Triphosphate | 1 | 2016 | 470 | 0.110 |
Why?
| Least-Squares Analysis | 1 | 2014 | 72 | 0.110 |
Why?
| Pharmacists | 1 | 2017 | 262 | 0.110 |
Why?
| Infant | 5 | 2020 | 8913 | 0.110 |
Why?
| Metabolic Clearance Rate | 2 | 2018 | 103 | 0.110 |
Why?
| Hypophosphatemia | 1 | 2013 | 15 | 0.110 |
Why?
| Cholecalciferol | 1 | 2014 | 57 | 0.110 |
Why?
| Double-Blind Method | 3 | 2013 | 1860 | 0.110 |
Why?
| Liver Diseases | 1 | 2016 | 285 | 0.110 |
Why?
| Diphosphates | 3 | 2021 | 17 | 0.110 |
Why?
| Calcitriol | 1 | 2013 | 55 | 0.100 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2013 | 66 | 0.100 |
Why?
| Tablets | 2 | 2023 | 37 | 0.100 |
Why?
| Leukocytes | 1 | 2014 | 303 | 0.100 |
Why?
| Desiccation | 1 | 2012 | 20 | 0.100 |
Why?
| Monocytes | 1 | 2015 | 541 | 0.100 |
Why?
| Kidney Diseases | 1 | 2016 | 368 | 0.100 |
Why?
| Case-Control Studies | 3 | 2024 | 3326 | 0.100 |
Why?
| Diabetes Mellitus | 1 | 2020 | 1001 | 0.100 |
Why?
| Organic Anion Transporters | 1 | 2011 | 10 | 0.100 |
Why?
| Benzoxazines | 1 | 2012 | 31 | 0.100 |
Why?
| Pravastatin | 1 | 2011 | 26 | 0.100 |
Why?
| Levonorgestrel | 1 | 2012 | 37 | 0.100 |
Why?
| Child, Preschool | 4 | 2021 | 10373 | 0.090 |
Why?
| Arylamine N-Acetyltransferase | 1 | 2011 | 5 | 0.090 |
Why?
| Benchmarking | 2 | 2024 | 176 | 0.090 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 177 | 0.090 |
Why?
| Nucleosides | 1 | 2011 | 26 | 0.090 |
Why?
| Specimen Handling | 1 | 2012 | 165 | 0.090 |
Why?
| Interferon-alpha | 1 | 2012 | 192 | 0.090 |
Why?
| Mental Disorders | 1 | 2019 | 1007 | 0.090 |
Why?
| Contraceptive Agents, Female | 1 | 2012 | 78 | 0.090 |
Why?
| Models, Statistical | 1 | 2015 | 625 | 0.090 |
Why?
| Raltegravir Potassium | 1 | 2010 | 17 | 0.090 |
Why?
| Hospitals, University | 1 | 2011 | 175 | 0.090 |
Why?
| Body Weight | 1 | 2015 | 931 | 0.090 |
Why?
| Patient Acceptance of Health Care | 1 | 2017 | 764 | 0.090 |
Why?
| Sex Distribution | 1 | 2011 | 359 | 0.080 |
Why?
| Cohort Studies | 2 | 2019 | 5369 | 0.080 |
Why?
| Aged | 5 | 2018 | 21971 | 0.080 |
Why?
| Sex Characteristics | 1 | 2015 | 727 | 0.080 |
Why?
| Dietary Supplements | 1 | 2014 | 529 | 0.080 |
Why?
| Mycobacterium tuberculosis | 1 | 2012 | 314 | 0.080 |
Why?
| Time Factors | 4 | 2016 | 6503 | 0.080 |
Why?
| Lamivudine | 2 | 2023 | 61 | 0.080 |
Why?
| Rosuvastatin Calcium | 1 | 2008 | 20 | 0.070 |
Why?
| Immunosuppressive Agents | 1 | 2012 | 686 | 0.070 |
Why?
| Pregnancy | 4 | 2025 | 6297 | 0.070 |
Why?
| Kidney Calculi | 1 | 2007 | 35 | 0.070 |
Why?
| Portugal | 1 | 2006 | 10 | 0.070 |
Why?
| Gene Frequency | 1 | 2008 | 504 | 0.070 |
Why?
| Education, Medical | 1 | 2009 | 244 | 0.060 |
Why?
| Quebec | 1 | 2006 | 10 | 0.060 |
Why?
| Furans | 1 | 2006 | 22 | 0.060 |
Why?
| Self Report | 2 | 2021 | 801 | 0.060 |
Why?
| Dementia | 1 | 2009 | 227 | 0.060 |
Why?
| Referral and Consultation | 1 | 2011 | 727 | 0.060 |
Why?
| Benzopyrans | 1 | 2025 | 31 | 0.060 |
Why?
| Sexual and Gender Minorities | 2 | 2019 | 186 | 0.060 |
Why?
| Internationality | 1 | 2006 | 148 | 0.060 |
Why?
| United States | 4 | 2017 | 13876 | 0.060 |
Why?
| Hematocrit | 2 | 2016 | 94 | 0.060 |
Why?
| Child | 4 | 2021 | 20721 | 0.060 |
Why?
| Lipids | 1 | 2008 | 624 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2019 | 1936 | 0.060 |
Why?
| Isoindoles | 1 | 2022 | 4 | 0.050 |
Why?
| Monkeypox virus | 1 | 2022 | 13 | 0.050 |
Why?
| Risk Assessment | 1 | 2012 | 3256 | 0.050 |
Why?
| Calibration | 2 | 2013 | 135 | 0.050 |
Why?
| Benzamides | 1 | 2022 | 194 | 0.050 |
Why?
| Demography | 1 | 2022 | 277 | 0.050 |
Why?
| Animals | 4 | 2022 | 34501 | 0.050 |
Why?
| Treatment Failure | 1 | 2023 | 342 | 0.050 |
Why?
| Computer Simulation | 2 | 2016 | 939 | 0.050 |
Why?
| Temperature | 2 | 2016 | 625 | 0.050 |
Why?
| Drug Approval | 1 | 2020 | 86 | 0.040 |
Why?
| Tissue Donors | 1 | 2023 | 386 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 1943 | 0.040 |
Why?
| Lactation | 1 | 2020 | 170 | 0.040 |
Why?
| Models, Biological | 2 | 2016 | 1693 | 0.040 |
Why?
| Developing Countries | 1 | 2020 | 283 | 0.040 |
Why?
| Chemistry Techniques, Analytical | 1 | 2018 | 19 | 0.040 |
Why?
| Flaviviridae | 1 | 2017 | 5 | 0.040 |
Why?
| Vero Cells | 1 | 2017 | 66 | 0.040 |
Why?
| Drug Repositioning | 1 | 2017 | 25 | 0.040 |
Why?
| Inhibitory Concentration 50 | 1 | 2017 | 81 | 0.040 |
Why?
| A549 Cells | 1 | 2017 | 58 | 0.040 |
Why?
| Hair | 1 | 2018 | 74 | 0.040 |
Why?
| Pharmaceutical Solutions | 1 | 2016 | 14 | 0.030 |
Why?
| Patient Selection | 1 | 2020 | 661 | 0.030 |
Why?
| Breast Feeding | 1 | 2020 | 421 | 0.030 |
Why?
| Chromatography, Reverse-Phase | 1 | 2016 | 27 | 0.030 |
Why?
| Drug Storage | 1 | 2016 | 53 | 0.030 |
Why?
| Cities | 1 | 2017 | 104 | 0.030 |
Why?
| Alcohol Drinking | 1 | 2023 | 749 | 0.030 |
Why?
| Defective Viruses | 1 | 2016 | 5 | 0.030 |
Why?
| Acute Disease | 1 | 2019 | 968 | 0.030 |
Why?
| Drug Compounding | 1 | 2016 | 95 | 0.030 |
Why?
| Solubility | 1 | 2016 | 229 | 0.030 |
Why?
| Methanol | 1 | 2016 | 33 | 0.030 |
Why?
| Spermatozoa | 1 | 2016 | 91 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2020 | 998 | 0.030 |
Why?
| Solutions | 1 | 2016 | 147 | 0.030 |
Why?
| Cold Temperature | 1 | 2016 | 151 | 0.030 |
Why?
| Blood-Brain Barrier | 1 | 2016 | 129 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2016 | 538 | 0.030 |
Why?
| Pregnancy Complications | 1 | 2020 | 488 | 0.030 |
Why?
| Administration, Inhalation | 1 | 2016 | 664 | 0.030 |
Why?
| Comorbidity | 1 | 2019 | 1540 | 0.030 |
Why?
| Logistic Models | 1 | 2020 | 1975 | 0.030 |
Why?
| Risk-Taking | 1 | 2017 | 348 | 0.030 |
Why?
| Interleukins | 1 | 2016 | 242 | 0.030 |
Why?
| DNA, Viral | 1 | 2016 | 348 | 0.030 |
Why?
| Recurrence | 1 | 2017 | 1001 | 0.030 |
Why?
| Feasibility Studies | 1 | 2017 | 860 | 0.030 |
Why?
| Vitamin D-Binding Protein | 1 | 2013 | 15 | 0.030 |
Why?
| Mental Health | 1 | 2019 | 684 | 0.030 |
Why?
| Algorithms | 1 | 2020 | 1616 | 0.030 |
Why?
| Parathyroid Hormone | 1 | 2013 | 106 | 0.030 |
Why?
| Water | 1 | 2016 | 444 | 0.020 |
Why?
| Therapeutic Equivalency | 1 | 2012 | 20 | 0.020 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 255 | 0.020 |
Why?
| Alkynes | 1 | 2012 | 54 | 0.020 |
Why?
| Cell Line | 1 | 2017 | 2731 | 0.020 |
Why?
| Anion Exchange Resins | 1 | 2011 | 7 | 0.020 |
Why?
| Zidovudine | 1 | 2011 | 77 | 0.020 |
Why?
| Food-Drug Interactions | 1 | 2010 | 8 | 0.020 |
Why?
| Reference Standards | 1 | 2011 | 170 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2018 | 2697 | 0.020 |
Why?
| Chemoprevention | 1 | 2010 | 89 | 0.020 |
Why?
| Latent Tuberculosis | 1 | 2011 | 68 | 0.020 |
Why?
| Epithelial Cells | 1 | 2016 | 1036 | 0.020 |
Why?
| Haplotypes | 1 | 2011 | 471 | 0.020 |
Why?
| Cholesterol | 1 | 2011 | 406 | 0.020 |
Why?
| Glomerular Filtration Rate | 1 | 2013 | 681 | 0.020 |
Why?
| Triglycerides | 1 | 2011 | 524 | 0.020 |
Why?
| Infant, Newborn | 1 | 2020 | 5687 | 0.020 |
Why?
| AIDS Dementia Complex | 1 | 2009 | 51 | 0.020 |
Why?
| Polymorphism, Genetic | 1 | 2011 | 639 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2017 | 4898 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2019 | 5040 | 0.020 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2009 | 222 | 0.020 |
Why?
| Positron-Emission Tomography | 1 | 2009 | 281 | 0.020 |
Why?
| Antiemetics | 1 | 1987 | 39 | 0.020 |
Why?
| Calcium | 1 | 2013 | 1178 | 0.020 |
Why?
| Vomiting | 1 | 1987 | 128 | 0.020 |
Why?
| Gene Expression Regulation | 1 | 2016 | 2506 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2018 | 7040 | 0.020 |
Why?
| Neuropsychological Tests | 1 | 2009 | 1003 | 0.010 |
Why?
| Brain | 1 | 2016 | 2618 | 0.010 |
Why?
| Age Factors | 1 | 2011 | 3117 | 0.010 |
Why?
| Alzheimer Disease | 1 | 2009 | 515 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2009 | 3366 | 0.010 |
Why?
| Antineoplastic Agents | 1 | 1987 | 2058 | 0.010 |
Why?
| Flunitrazepam | 1 | 1987 | 3 | 0.000 |
Why?
| Metoclopramide | 1 | 1987 | 17 | 0.000 |
Why?
| Methylprednisolone | 1 | 1987 | 82 | 0.000 |
Why?
|
|
Kiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|